BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
BTAI Price/Volume Stats
| Current price | $1.43 | 52-week high | $18.24 |
| Prev. close | $1.59 | 52-week low | $1.17 |
| Day low | $1.39 | Volume | 390,200 |
| Day high | $1.59 | Avg. volume | 2,143,070 |
| 50-day MA | $1.71 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 8.66M |
BTAI Stock Price Chart Interactive Chart >
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
BTAI Price Returns
| 1-mo | -27.41% |
| 3-mo | -19.66% |
| 6-mo | -72.58% |
| 1-year | -92.02% |
| 3-year | -99.35% |
| 5-year | -99.80% |
| YTD | -76.10% |
| 2024 | -87.33% |
| 2023 | -86.27% |
| 2022 | 5.66% |
| 2021 | -56.00% |
| 2020 | 216.22% |
Loading social stream, please wait...